<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>7</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2013</Year>
        <Month>03</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Epstein-Barr Virus-Induced Hemophagocytic Lymphohistiocytosis</title>
    <FirstPage>39</FirstPage>
    <LastPage>42</LastPage>
    <AuthorList>
      <Author>
        <FirstName>K</FirstName>
        <LastName>Goudarzipour</LastName>
        <affiliation locale="en_US">Mofid, Children's Hospital, shahid beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>M</FirstName>
        <LastName>Kajiyazdi</LastName>
        <affiliation locale="en_US">Mofid, Children's Hospital, shahid beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>A</FirstName>
        <LastName>Mahdaviyani</LastName>
        <affiliation locale="en_US">Masih Daneshvari Hospital, shahid beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>14</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Hemophagocytic lymphohistiocytosis (HLH) is one of the complications of Epstein-Barr virus (EBV) infection. Although the patients who have developed HLH following EBV have normal immune system, there are a few patients with EBV-induced immune deficiency who develop HLH as well. Here, we describe the case of a 10-year-old girl with neurological complications caused by EBV-induced HLH. The patient received rituximab, leading to weakening inflammation associated with EBV infection and suppression of disease through quick treatment.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/462</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/462/335</pdf_url>
  </Article>
</Articles>
